United States - English - myHealthbox

ecolab -

United States - English - NLM (National Library of Medicine)

acrotech biopharma llc - vincristine sulfate (unii: t5iro3534a) (vincristine - unii:5j49q6b70f) - marqibo® is indicated for the treatment of adult patients with philadelphia chromosome negative (ph-) acute lymphoblastic leukemia (all) in second or greater relapse or whose disease has progressed following two or more anti leukemia therapies. this indication is approved under accelerated approval based on overall response rate [see clinical studies (14)]. continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). marqibo is contraindicated in patients with demyelinating conditions, including charcot-marie-tooth syndrome. marqibo is contraindicated in patients with hypersensitivity to vincristine sulfate or any of the other components of marqibo (vincristine sulfate liposome injection). marqibo is contraindicated for intrathecal administration risk summary based on findings from nonclinical studies and its mechanism of action, marqibo can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1 ),

Singapore - English - HSA (Health Sciences Authority)

ferring pharmaceuticals private limited - progesterone, micronized - tablet, effervescent - progesterone, micronized 100.0 mg

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

agritech enterprise sdn. bhd. - gamithromycin -

New Zealand - English - Ministry for Primary Industries

divasa-farmavic s.a. - penethamate hydriodide - penethamate hydriodide 994.7 g/kg - antibiotic